Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wainwright 3.25 target is way off the mark ...This technology will open huge markets for ASP Isotopes during 2024 projecting future revenues with further offtake agreements and JVs.during 2024-2025
total amount of land up to 182 acres. This land increase is a necessary step to provide sufficient feedstock for the next step up in capacity after the recent success of the pilot line.The land should provide sufficient feedstock to create around 500,000 gallons of ethanol per year.
Not saying 5 over nite but with the unique low cost process and right major involved it could be a 1. Billion plus valuation or easily a buyout far above where it is now
Uncle Bens converted rice..er....switchgrass.... little joke needed here .
If they decide to go it alone with a partner build a plant for say 10 mill , with a number of possible jvers Ben might be thinking that the company would be worth much more as a going concern making money that would lead to an eventual buy out...the risk of certification now might allow a major player to end run the technology if they can produce at scale there's no need for process certification except for the end product.
there are 301 million shares outstanding. At 1 dollar its a 7.7x from here or 300 million mkt cap .Should they partner and be able to produce and sell at scale ...a 300 million mkt cap could translate to a 5 dollar valuation ..just based on the fact that no one has been able to produce at super low cost at scale.. The market has faced multiple failures with untold hundred millions spent. One could assume an oil giant could swallow them up easily. paying several billion. all this silence and their low cash levels suggests we should find out something soon. ?
Amid silence putting out videos might suggest they are trolling for prospects to invest .....sure seems a mystery at best
time to step up and cut a deal ....if there is one.
The question is...is there enough room to do a financing to produce revenues?? pushing out any real production another 18-24 months
my guess is it BIG DEAL TIME for all concerned.... lets hope...fingers crossed......BIOF..it's time for your close up shot..... take it.
After several years of perfecting the process they seem to have decided to seek govt funding and produce independently rather than JV or partner with a major player in the space . Negotiating with the govt takes time. Ben seems determined.
GRIL usually prints the monthly revs etc mid month nice recovery today hmmmmm....... 1.11 to 1.25
getting rid of the day traders all hoping it would soar real value buyers moving in
Everyone seems to regard Sadot as static....Sadot /Aggia can spin off restaurants . Since they have no debt they can issue more stock grow the business...and in 2 years + plus sell this cash flow operation to many potential buyers for far more than 3-5 a share ....they seem to be in the drivers seat ...This is a no brainer
Get the restaurants on a ramp to break even ASAP ...spin them off and ride the gravy train...
perhaps SADOT might be a nice cash flow acquisition = BIG payday
As long as its kept under wraps the tech wont be reviewed or stolen ...seems like that's the medium term anyway .Hopefully there wont be alternative battery advancements although there wont be planes flying on batteries anytime soon.
Seems like Ben wants to profitably operate a plant and potentially be able to go it alone...without a partner or find a JV where its 80 / 20 with a major .Seems like he's holding all the cards but there's alot to be said for legal and other protection along with rapid mega commercial start up with a Major JV partner . IF they engage in exploratory discussions now it would clearly shorten the time to deploy the technology ...hence make money ,,,hence the stock would reflect that..or it may just be they are afraid the tech could be easily modified or stolen....time will tell
Things can come for those who wait....long enough ....
Compass to review latest phase 2 progress with CTX 009 and other items at ASCO Jan 19-21.
Company moving slowly into the spotlight.
No one has been able to achieve what they are attempting ...at this point they are very optomistic...I say ...go with it.!!
Reminder CMPX is Compass Therapeutics ,,,EF Hutton new target 10
targets range from 8-15
amazing no one posts on any CMPX boards except twitter ...and even then crickets
The proper company name associated with CMPX symbol
Compass Therapeutics . If one were to review the 6 or 7 bispecifics currently approved for cancer, the efficacy of CTX 009 , CTX 471 and CTX 8371 in early trials is astounding...with a very unique Moa...still not understood by most analysts. It clearly warrants a collaboration with Merck on 471 and potentially many others. The stitchmab they have developed is a real game changing technology optimizing the best suitable mab combinations , along with Taxol, Keytruda and others ...supercharging the efficacy of current drug therapies. This stock has multiple undervalued assets.
Do you think they like their company ...a little??
Compass Therapeutics, Inc. Insider Trading Activity (benzinga.com)
Is something about to happen in 6 weeks ??? fill us in ,
More exposure to potential investors, partners, underwriters etc... the public isnt going to charge into this ...Jim Lane has many connections
The relative outperformance continues stock sits at 3.05 .Phase 2/3 in US will begin Q4 ...more oustanding data to follow. 3X is easy with this one.
Its really an apples and oranges comparison...CRXM is attempting to prevent what
Tenaya is servicing which is heart failure . CRXM mkt is clearly a much larger one Tenaya is attempting to relieve heart stress before failure thru heart muscle regenerative stimulation in MIce , yet fails to minimize the underlying causes one of which CRXM addresses that of narrowing arteries.I cant begin to understand or explain it all here . Great post underscoring the present value of CRXM My est possibly a 1 for 3 reverse if any .... should be a 200 -300 million market cap...IMHO
As far as I know they are on track for Sept....we would want to see pretesting before any limited field work ..releasing a properly functioning bench tested unit is key to successful field tests .Could there be a week or two or three weeks longer possibly.
As I understand it there are less size issues going forward as they plan to run several units simultaneously to achieve volume production...we are getting seriously.....closer
No direct competition ...different tech different feedstock. Cellulosic is coming into its own and Komarek is not only building but testing the machine as well prior to pre commercial field testing ....investors won't have to wait much longer to see validation of the process. One can assume Komarek will more than likely be involved with any JVs or partnerships forward.
companies are moving forward in the cellulosic arena:
https://www.globenewswire.com/news-release/2022/08/18/2501037/0/en/Comstock-Cellulosic-Ethanol-Technology-Ready-For-Commercial-Deployment.html
CEO continues to buy stock buys another 15000 filed 8/17 owns over 5.3 million shares
https://ih.advfn.com/stock-market/NASDAQ/compass-therapeutics-CMPX/stock-news/88862025/statement-of-changes-in-beneficial-ownership-4
It would appear that there is still a game to be played starting in January 2023 ...I believe we have seen this date rolled forward several times??? Is this one anticipated
to actually occur ?? Would like to see funding announcement ...that would be a game changer.
Now we're talking !! 3.00 then 3.27 news might be coming fairly soon
New data plus CTX 009 US trial enrollment . winner..
I heard the same on CNBC Sirius radio yesterday. Can't imagine who would suggest to rely on retail investors to raise the stock price. The only reason would be to try to do a stock related deal rather than securing a large partner ...so far neither of which seems plausible in the near future.
well one thing is certain Nostrum has cleaned up alot of mess in the past nightmare cash burning with no result ....from 2020 still....... optimistic ......
https://m.marketscreener.com/news/latest/Generex-Biotechnology-SEC-Filing-10-Q-Quarterly-Report--30197956/
From what I know this proposal has been there for awhile .If this is a new filing then it was amended recently. What I'd like to know is how are existing shareholders affected.dilution comes to mind but if sucessful its dimunitive. Nostrum pays 3 million raises 6 million for some participation in Generex ??? In the end it would be nice to hear from Nostrum about the plan forward....IPO is mentioned...how would that apply..Reinhardt cant shoulder the raise alone.
they are attempting to offer various technologies to lure future money providers !!!... I agree there are many holes in their statements corn is nothing new and they just bought 245 acres ..they mention low carbon corn ??? hmmmmm....maybe they're betting that jet fuel will become so expensive that what ever they make will be break even and help the enviornment albeit with still a "low carbon " footprint....its still a show me and their stock price reflects that. .Blue Biofuels process is a winning one provided they can deliver with scale ..just the feedstock has distinct advantages over many agricultural .GEVO does mention biodegradable plastics (100% carbon free?) from lignin where there are several cos already doing that;
Seems like there is a certain vagueness about their end products and the degree of "low carbon products"..they are using corn another pipe dream ??? or profitable?
https://www.globenewswire.com/news-release/2022/07/25/2485106/23976/en/Gevo-Closes-on-Net-Zero-1-Production-Facility-Land-in-Lake-Preston-SD-Plans-Fall-Groundbreaking.html
What Blue Biofuels is attempting is way way ahead of them
Do we have to wait for a " no symbol " . I guess Nostrum has temporarily or permanently abandoned this ticker....they do own something the rights to the tech.....we'd all like to know ...a partner on this company would truly be pulling a rabbit out of a hat !!! This takes piles of money
Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart Disease.
Lets just say I will find a way to take my loss by year end ..as time passes with nothing from either Nostrum or CRXM its becoming quite clear ..they are getting too far gone to even have relevent data or much of anything...Nostrum was Reinhardt's last life line ....Ask yourself would you partner with this at this point ??...feeling more like a write off now...Rah Rahs dont cut it anymore.